Editor’s Note
**Editor’s Note:** Hugel has officially entered India’s botulinum toxin market, targeting a 9% share this year. The move leverages India’s large population and growing K-beauty interest, supporting the company’s broader Asia-Pacific expansion strategy.
By Hong Da-yeong
Published 2026.07.22. 17:53
Updated 2026.07.22. 17:59
Hugel announces it enters India with its botulinum toxin, Letybo. /Courtesy of Hugel
Hugel (221,500 won ▼ 7,000 -3.06%) said on the 22nd that it has entered the Indian Botox (botulinum toxin) market. India has a population of 1.5 billion, and interest in K-beauty is high among the middle class. Hugel aims to achieve a 9% market share in India this year.
Hugel recently took part in a global aesthetics summit held in India and unveiled its Botox, Letibo. Botox is a toxic protein extracted from the botulinum bacterium. When injected into the skin, it paralyzes muscles, temporarily smoothing fine lines.
Hugel is holding a product event with its local distributor, Aka Medical, through the 24th. It is also preparing academic exchanges and workshops. Hugel plans to use India as a base to accelerate its expansion into the Asia-Pacific.
— Jang Doo-hyun, Hugel’s CEO
※ This article has been translated by AI. Share your feedback here.